Morgan Stanley’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.96M | Buy |
544,268
+88,924
| +20% | +$320K | ﹤0.01% | 4718 |
|
|
2025
Q1 | $1.36M | Sell |
455,344
-111,696
| -20% | -$334K | ﹤0.01% | 4843 |
|
|
2024
Q4 | $1.9M | Buy |
567,040
+78,141
| +16% | +$262K | ﹤0.01% | 4732 |
|
|
2024
Q3 | $1.64M | Buy |
488,899
+121,359
| +33% | +$407K | ﹤0.01% | 4766 |
|
|
2024
Q2 | $1.22M | Sell |
367,540
-37,099
| -9% | -$123K | ﹤0.01% | 4843 |
|
|
2024
Q1 | $1.63M | Sell |
404,639
-410,673
| -50% | -$1.66M | ﹤0.01% | 4697 |
|
|
2023
Q4 | $2.49M | Buy |
815,312
+550,220
| +208% | +$1.68M | ﹤0.01% | 4803 |
|
|
2023
Q3 | $795K | Sell |
265,092
-164,404
| -38% | -$493K | ﹤0.01% | 4930 |
|
|
2023
Q2 | $1.61M | Sell |
429,496
-47,689
| -10% | -$178K | ﹤0.01% | 4557 |
|
|
2023
Q1 | $1.6M | Buy |
477,185
+37,951
| +9% | +$127K | ﹤0.01% | 4586 |
|
|
2022
Q4 | $2.11M | Sell |
439,234
-57,746
| -12% | -$278K | ﹤0.01% | 4425 |
|
|
2022
Q3 | $2.83M | Buy |
496,980
+104,464
| +27% | +$594K | ﹤0.01% | 4174 |
|
|
2022
Q2 | $2.79M | Sell |
392,516
-36,105
| -8% | -$256K | ﹤0.01% | 4278 |
|
|
2022
Q1 | $3.1M | Sell |
428,621
-214,121
| -33% | -$1.55M | ﹤0.01% | 4171 |
|
|
2021
Q4 | $5.75M | Buy |
642,742
+200,056
| +45% | +$1.79M | ﹤0.01% | 3570 |
|
|
2021
Q3 | $15.5M | Sell |
442,686
-346,662
| -44% | -$12.2M | ﹤0.01% | 2373 |
|
|
2021
Q2 | $17M | Buy |
789,348
+731,027
| +1,253% | +$15.7M | ﹤0.01% | 2334 |
|
|
2021
Q1 | $3.6M | Sell |
58,321
-48,266
| -45% | -$2.98M | ﹤0.01% | 3750 |
|
|
2020
Q4 | $4.45M | Buy |
+106,587
| New | +$4.45M | ﹤0.01% | 3385 |
|